Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
62,337,402
-
Total 13F shares
-
29,539,370
-
Share change
-
-4,314,732
-
Total reported value
-
$10,842,560
-
Put/Call ratio
-
0%
-
Price per share
-
$0.37
-
Number of holders
-
62
-
Value change
-
-$793,553
-
Number of buys
-
35
-
Number of sells
-
54
Institutional Holders of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) as of Q2 2025
As of 30 Jun 2025,
Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,539,370 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., BML Capital Management, LLC, Aisling Capital Management LP, VANGUARD GROUP INC, Opaleye Management Inc., DELTEC ASSET MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Rangeley Capital, LLC, and ExodusPoint Capital Management, LP.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.